106
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Organocatalytic [3 + 2] Cycloaddition Reaction: Synthesis of Fully Decorated Sulfonyl-1,2,3-Triazolyl Pyrimidines as Potent Anticancer and EGFR Inhibitors

& ORCID Icon
Pages 2675-2687 | Received 10 Apr 2023, Accepted 28 May 2023, Published online: 10 Jun 2023
 

Abstract

A general strategy was developed for the synthesis of new fully decorated sulfonyl1,2,3-triazolyl pyrimidines (6a–6j and 8a–8f) from 2-((6-methyl-2-(methylsulfonyl)pyrimidin-4-yl)sulfonyl)-1-(4-nitrophenyl)ethanone and several azides in the presence of catalytic amounts of organocatalyst. Ramachary OrgAKC reaction of β-ketosulfone (4) acts as an internal alkyne as reported for the synthesis of sulfonyl-1,2,3-triazolyl pyrimidines at 80 °C in good to excellent yields of products in the presence of catalytic amounts of pyrrolidine (10 mol %). In vitro anticancer activity of all these derivatives revealed that six compounds like 6d, 6e, 6g, 6h, 8c, and 8d were active against three human cancer cell lines like breast carcinoma, cervical carcinoma, and alveolar carcinoma. In specific, compounds 6g and 6h showed superior activity against tested cell lines compared to the standard drug erlotinib. Later, the results of inhibitory assay of potent compounds 6d, 6e, 6g, 6h, 8c, and 8d against the tyrosine kinase epidermal growth factor receptor (EGFR) revealed that compounds 6g and 6h showed more potency than the reference drug erlotinib.

Acknowledgments

The authors are thankful to the head, Department of Biotechnology, Kakatiya University, Warangal, for providing data of biological activity.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.